Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Clinical Cancer Research2015Vol. 22(10), pp. 2470–2481
Citations Over TimeTop 10% of 2015 papers
Anton G. Henssen, Kristina Althoff, Andrea Odersky, Anneleen Beckers, Richard P. Koche, Frank Speleman, Simon Schäfers, Emma Bell, Maike Nortmeyer, Frank Westermann, Katleen De Preter, Alexandra Florin, Lukas C. Heukamp, Annika Spruessel, Kathy Astrahanseff, Sven Lindner, Natalie Sadowski, Alexander Schramm, Lucile Astorgues‐Xerri, María E. Riveiro, Angelika Eggert, Esteban Cvitkovic, Johannes H. Schulte
Abstract
We show that OTX015 is effective against mouse and human MYCN-driven tumor models and that BRD4 not only targets MYCN, but specifically occupies MYCN target gene enhancers as well as other genes associated with super-enhancers. Clin Cancer Res; 22(10); 2470-81. ©2015 AACR.
Related Papers
- → Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain(2018)118 cited
- → Overexpression of bromodomain factor 3 in Trypanosoma cruzi (TcBDF3) affects differentiation of the parasite and protects it against bromodomain inhibitors(2016)38 cited
- → Epigenetic Therapy Beneficial in Blood Cancers(2014)1 cited
- → Structural insights into the recognition of mono- and di-acetylated histones by the ATAD2B bromodomain(2018)
- → ИСПОЛЬЗОВAНИЕ ПОТЕНЦИAЛA СОЦИAЛЬНЫХ ПAРТНЕРОВ В ПОДГОТОВКЕ БУДУЩИХ ПЕДAГОГОВ(2024)